Latest News for TCRT
Alaunos Therapeutics Inc. (NASDAQ: TCRT) shares are down on Monday after the company announced preclinical proof-of-concept data for its lead drug candidate, ALN1003.
Alaunos' ALN1003 shows dose dependent weight loss, better body composition, reduced liver weight, and improved liver biomarkers in preclinical studies.
Alaunos Therapeutics, Inc. (NASDAQ: TCRT - Get Free Report) saw a significant decline in short interest in January. As of January 30th, there was short interest totaling 44,597 shares, a decline of 14.6% from the January 15th total of 52,250 shares. Based on an average daily trading volume, of 15,766 shares, the short-interest ratio is currently
Alaunos Therapeutics, Inc. (NASDAQ: TCRT - Get Free Report) was up 3.1% during mid-day trading on Wednesday. The company traded as high as $3.00 and last traded at $3.00. Approximately 16,982 shares changed hands during mid-day trading, a decline of 48% from the average daily volume of 32,426 shares. The stock had previously closed at
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TCRT.
U.S. House Trading
No House trades found for TCRT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.